We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
References
1
Meldrum, DR, Chang, RJ, de Ziegler, D, et al. Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs?Fertil Steril2009;92:13–18.Google Scholar
2
Meldrum, DR, Wisot, A, Hamilton, F, et al. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertil Steril1989;51:455–459.Google Scholar
3
Hughes, EG, Fedorkow, DM, Daya, S, et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril1992;58:888–896.CrossRefGoogle ScholarPubMed
4
Tarlatzis, BC, Fauser, BC, Kolibianakis, EM, et al. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update2006;12:333–340.CrossRefGoogle ScholarPubMed
5
Lambalk, CB, Banga, FR, Huirne, JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update2017;23:560–579.Google Scholar
6
Biljan, MM, Mahutte, NG, Dean, N, et al. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril1998;70:1063–1069.CrossRefGoogle ScholarPubMed
7
van Heusden, AM, Fauser, BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception1999;59:237–243.Google Scholar
8
de Ziegler, D, Jaaskelainen, AS, Brioschi, PA, Fanchin, R, Bulletti, C.Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod1998;13:561–564.Google Scholar
9
Fanchin, R, Salomon, L, Castelo-Branco, A, et al. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod2003;18:2698–2703.Google Scholar
10
Frattarelli, JL, Hill, MJ, McWilliams, GD, et al. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril2008;89:1118–1122.Google Scholar
11
Daly, DC, Walters, CA, Soto-Albors, CE, Tohan, N, Riddick, DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril1984;41:844–848.Google Scholar
12
Parsanezhad, ME, Alborzi, S, Motazedian, S, Omrani, G.Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril2002;78:1001–1004.CrossRefGoogle Scholar
13
Elnashar, A, Abdelmageed, E, Fayed, M, Sharaf, M.Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod2006;21:1805–1808.Google Scholar
14
Keay, SD, Lenton, EA, Cooke, ID, Hull, MG, Jenkins, JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod2001;16:1861–1865.Google Scholar
15
Thurston, LM, Norgate, DP, Jonas, KC, et al. Ovarian modulators of type 1 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity and intra-follicular cortisol:cortisone ratios correlate with the clinical outcome of IVF. Hum Reprod2003;18:1603–1612.Google Scholar
16
Lewicka, S, von Hagens, C, Hettinger, U, et al. Cortisol and cortisone in human follicular fluid and serum and the outcome of IVF treatment. Hum Reprod2003;18:1613–1617.Google Scholar
17
Simerman, AA, Hill, DL, Grogan, TR, et al. Intrafollicular cortisol levels inversely correlate with cumulus cell lipid content as a possible energy source during oocyte meiotic resumption in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril2015;103:249–257.CrossRefGoogle ScholarPubMed
18
Palomba, S, Falbo, A, La Sala, GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG2013;120:267–276.CrossRefGoogle ScholarPubMed
19
Agrawal, R, Jacobs, H, Payne, N, Conway, G.Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril2002;78:1164–1169.Google Scholar
20
Creanga, AA, Bradley, HM, McCormick, C, Witkop, CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol2008;111:959–968.Google Scholar
21
Stadtmauer, LA, Toma, SK, Riehl, RM, Talbert, LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril2001;75:505–509.Google Scholar
22
Tang, T, Glanville, J, Orsi, N, Barth, JH, Balen, AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod2006;21:1416–1425.Google Scholar
23
Jakubowicz, DJ, Seppala, M, Jakubowicz, S, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab2001;86:1126–1133.Google ScholarPubMed
24
Cermik, D, Selam, B, Taylor, HS. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab2003;88:238–243.Google Scholar
25
Jakubowicz, DJ, Iuorno, MJ, Jakubowicz, S, Roberts, KA, Nestler, JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab2002;87:524–529.Google Scholar
26
De Leo, V, la Marca, A, Ditto, A, Morgante, G, Cianci, A.Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril1999;72:282–285.Google Scholar
27
Meldrum, DR, Scott, RT, Jr., Levy, MJ, Alper, MM, Noyes, N.Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss. Fertil Steril2009;91:1963–1965.Google Scholar
28
Acevedo, B, Sanchez, M, Gomez, JL, et al. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril2004;82:343–347.Google Scholar
29
The ganirelix dose-finding group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod1998;13:3023–3031.CrossRefGoogle Scholar
30
Kolibianakis, EM, Zikopoulos, K, Schiettecatte, J, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod2004;19:24902496.Google Scholar
31
Coomarasamy, A, Afnan, M, Cheema, D, et al. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod2008;23:310–315.Google Scholar
32
Thompson, KA, LaPolt, PS, River, J, et al. Gonadotropin requirements of the developing follicle. Fertil Steril1995;63:273–276.Google Scholar
33
Rubinstein, M, Marazzi, A, Polak de Fried, E. Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: a prospective, randomized, double-blind placebo-controlled assay. Fertil Steril1999;71:825–829.Google Scholar
34
Ebbesen, SM, Zachariae, R, Mehlsen, MY, et al. Stressful life events are associated with a poor in-vitro fertilization (IVF) outcome: a prospective study. Hum Reprod2009;24:2173–2182.Google Scholar
35
Siristatidis, CS, Basios, G, Pergialiotis, V, Vogiatzi, P.Aspirin for in vitro fertilisation. Cochrane Database Syst Rev2016;11:CD004832.Google Scholar
36
Varnagy, A, Bodis, J, Manfai, Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril2010;93:2281–2284.Google Scholar
37
Bencomo, E, Perez, R, Arteaga, MF, et al. Apoptosis of cultured granulosa-lutein cells is reduced by insulin-like growth factor I and may correlate with embryo fragmentation and pregnancy rate. Fertil Steril2006;85:474–480.Google Scholar
38
Harper, K, Proctor, M, Hughes, E.Growth hormone for in vitro fertilization. Cochrane Database Syst Rev2003;3:CD000099.Google Scholar
39
Tesarik, J, Hazout, A, Mendoza, C.Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Hum Reprod2005;20:2536–2541.CrossRefGoogle ScholarPubMed
40
Kolibianakis, EM, Venetis, CA, Diedrich, K, Tarlatzis, BC, Griesinger, G.Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update2009;15:613–622.Google Scholar
41
Li, XL, Wang, L, Lv, F, et al. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: a systematic review and meta-analysis. Medicine (Baltimore)2017;96:e6443.Google Scholar
42
Meldrum, DR, Quaas, AM, Su, HI. Why is growth hormone underutilized for our most difficult IVF couples?Fertil Steril2018;110:1261–1262.Google Scholar
43
Alvarez, C, Marti-Bonmati, L, Novella-Maestre, E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab2007;92:2931–2937.Google Scholar
44
Levin, ER, Rosen, GF, Cassidenti, DL, et al. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest1998;102:1978–1985.Google Scholar
45
Ferraretti, AP, Gianaroli, L, Diotallevi, L, Festi, C, Trounson, A.Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod1992;7:180–183.Google Scholar
46
Alvarez, C, Alonso-Muriel, I, Garcia, G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod2007;22:3210–3214.CrossRefGoogle ScholarPubMed
47
Vendola, KA, Zhou, J, Adesanya, OO, Weil, SJ, Bondy, CA. Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest1998;101:2622–2629.Google Scholar
48
Balasch, J, Fabregues, F, Penarrubia, J, et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod2006;21:1884–1893.Google Scholar
49
Kim, CH, Howles, CM, Lee, HA. The effect of transdermal testosterone gel pretreatment on controlled ovarian stimulation and IVF outcome in low responders. Fertil Steril2011;95:679–683.Google Scholar
50
Garcia-Velasco, JA, Moreno, L, Pacheco, A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril2005;84:82–87.Google Scholar
51
Schoolcraft, WB, Surrey, ES, Minjarez, DA, Stevens, JM, Gardner, DK. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?Fertil Steril2008;89:151–156.Google Scholar
52
Song, Y, Li, Z, Wu, X, et al. Effectiveness of the antagonist/letrozole protocol for treating poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Gynecol Endocrinol2014;30:330–334.Google Scholar
53
Frattarelli, JL, Gerber, MD. Basal and cycle androgen levels correlate with in vitro fertilization stimulation parameters but do not predict pregnancy outcome. Fertil Steril2006;86:51–57.Google Scholar
54
Barad, D, Gleicher, N.Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod2006;21:2845–2849.Google Scholar
55
Barad, D, Brill, H, Gleicher, N.Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet2007;24:629–634.Google Scholar
56
Nagels, HE, Rishworth, JR, Siristatidis, CS, Kroon, B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev2015;11:CD009749.Google Scholar
57
Paulson, RJ. At last, an orally active gonadotropin-releasing hormone antagonist. Fertil Steril2019;111:30–31.Google Scholar
References
1
Gougeon, A.Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod1986;1:81–87.Google Scholar
2
Messinis, IE, Messini, CI, Dafopoulos, K.The role of gonadotropins in the follicular phase. Ann N Y Acad Sci2010;1205:5–11.Google Scholar
3
Messinis, IE. Mechanisms of follicular development: the role of gonadotrophins. In: Rizk, B, Garcia-Velasco, J, Sallam, H, Makrigiannakis, A., eds. Infertility and Assisted Reproduction. Cambridge: Cambridge University Press; 2008:3–24.Google Scholar
4
van Santbrink, EJ, Hop, WC, van Dessel, TJ, de Jong, FH, Fauser, BC. Decremental follicle-stimulating hormone and dominant follicle development during the normal menstrual cycle. Fertil Steril1995;64:37–43.Google Scholar
5
Mihm, M, Baker, PJ, Ireland, JL, et al. Molecular evidence that growth of dominant follicles involves a reduction in follicle-stimulating hormone dependence and an increase in luteinizing hormone dependence in cattle. Biol Reprod2006;74:1051–1059.Google Scholar
6
Hillier, SG. Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol2001;179:39–46.Google Scholar
7
Garg, D, Tal, R.The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online2016;33:15–28.Google Scholar
8
Erickson, GF, Shimasaki, S.The role of the oocyte in folliculogenesis. Trends Endocrinol Metab2000;11:193–198.Google Scholar
9
Messinis, IE, Templeton, AA. Pituitary response to exogenous LHRH in superovulated women. J Reprod Fertil1989;87:633–639.Google Scholar
10
Messinis, IE, Milingos, S, Zikopoulos, K, et al. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone. Hum Reprod1998;13:2415–2420.Google Scholar
11
Messinis, IE, Messini, CI, Anifandis, G, Garas, A, Daponte, A.Gonadotropin surge-attenuating factor: a nonsteroidal ovarian hormone controlling GnRH-induced LH secretion in the normal menstrual cycle. Vitam Horm2018;107:263–286.Google Scholar
12
Cedrin-Durnerin, I, Bidart, JM, Robert, P, et al. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization. Hum Reprod2000;15:1009–1014.Google Scholar
13
Borm, G, Mannaerts, B.Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod2000;15:1490–1498.Google ScholarPubMed
14
Felberbaum, RE, Albano, C, Ludwig, M, et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod2000;15:1015–1020.Google Scholar
15
Propst, AM, Hill, MJ, Bates, GW, et al. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril2011;96:898–904.Google Scholar
16
Fleming, R, Lloyd, F, Herbert, M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod1998;13:1788–1792.Google Scholar
17
Bosch, E, Vidal, C, Labarta, E, et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists: a randomized study. Hum Reprod2008;23:2346–2351.Google Scholar
18
van Wely, M, Kwan, I, Burt, AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev2011;2:CD005354.Google Scholar
19
Tarlatzis, B, Tavmergen, E, Szamatowicz, M, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod2006;21:90–94.CrossRefGoogle ScholarPubMed
20
NyboeAndersen, A, Humaidan, P, Fried, G, et al.; Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Hum Reprod2008;23:427–434.Google Scholar
21
Franco, JG Jr., Baruffi, RL, Oliveira, JB, et al. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study. Reprod Biol Endocrinol2009;7:58.Google Scholar
22
Kolibianakis, EM, Kalogeropoulou, L, Griesinger, G, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update2007;13:445–452.Google Scholar
23
Al-Inany, HG, Abou-Setta, AM, Aboulghar, MA, Mansour, RT, Serour, GI. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol2009;25:372–378.Google Scholar
24
Mochtar, MH, Danhof, NA, Ayeleke, RO, Van der Veen, F, van Wely, M.Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev2017;5:CD005070.Google Scholar
25
Thuesen, LL, Loft, A, Egeberg, AN, et al. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Hum Reprod2012;27:3074–3084.Google Scholar
26
Requena, A, Cruz, M, Ruiz, FJ, García-Velasco, JA. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin. Reprod Biol Endocrinol2014;12:10.Google Scholar
27
Messinis, IE, Templeton, AA. Disparate effects of endogenous and exogenous oestradiol on luteal phase function in women. J Reprod Fertil1987;79:549–554.Google Scholar
28
Martins, WP, Ferriani, RA, Navarro, PA, Nastri, CO. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol2016;47:144–151.Google Scholar
29
van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M.Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev2015;7:CD009154.Google Scholar
30
Mochtar, MH, Van der Veen, F, Ziech, M, van Wely, M. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev2007;2:CD005070.Google Scholar
31
Matorras, R, Prieto, B, Exposito, A, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online2009;19:879–887.Google Scholar
32
Bosch, E, Labarta, E, Crespo, J, et al. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril2011;95:1031–1036.Google Scholar
33
König, TE, van der Houwen, LE, Overbeek, A, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod2013;28:2804–2812.Google Scholar
34
Hill, MJ, Levens, ED, Levy, G, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril2012;97:1108.e1–1114.e1.Google Scholar
35
Lehert, P, Kolibianakis, EM, Venetis, CA, et al. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. Reprod Biol Endocrinol2014;12:17.CrossRefGoogle ScholarPubMed
36
Humaidan, P, Chin, W, Rogoff, D, et al.; ESPART Study Investigators. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod2017;32:544–555.CrossRefGoogle ScholarPubMed
37
Revelli, A, Chiado’, A, Guidetti, D, et al. Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study. J Assist Reprod Genet2012;29:869–875.Google Scholar
38
Messinis, IE, Bergh, T, Wide, L.The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril1988;50:31–35.Google Scholar
39
Lewit, N, Kol, S.The low responder female IVF patient with hypogonadotropic hypogonadism: do not give up!Fertil Steril2000;74:401–402.Google Scholar
40
Pandurangi, M, Tamizharasi, M, Reddy, NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Hum Reprod Sci2015;8:146–150.Google Scholar
41
Durnerin, CI, Erb, K, Fleming, R, et al.; Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod2008;23:421–426.Google Scholar
42
Sullivan, MW, Stewart-Akers, A, Krasnow, JS, Berga, SL, Zeleznik, AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab1999;84:228–232.Google Scholar
43
Yong, EL, Baird, DT, Yates, R, Reichert, LE Jr., Hillier, SG. Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab1992;74:842–849.Google Scholar
44
Loumaye, E, Engrand, P, Shoham, Z, Hillier, SG, Baird, DT. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod2003;18:314–322.Google Scholar
45
Baird, DT. Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician’s point of view. Hum Reprod2001;16:1316–1318.Google Scholar
References
1
The Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril2008;90:S219–S225.Google Scholar
2
Bulun, SE, Adashi, EY. The physiology and pathology of the female reproductive axis. In: Melmed, S, Polonsky, KS, Larsen, PR, Kronenberg, HM, eds. Williams Textbook of Endocrinology, 13th ed. Philadelphia: Elsevier Health Sciences; 2015:590–663.Google Scholar
3
Fevold, HL. Synergism of follicle stimulating and luteinizing hormones in producing estrogen secretion. Endocrinology1941;28:33–36.Google Scholar
4
Richards, JS. Hormonal control of gene expression in the ovary. Endocr Rev1994;15:725–751.Google Scholar
5
Erickson, GF, Magoffin, DA, Dyer, CA, Hofeditz, C.The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev1985;6:371–399.Google Scholar
6
Angelopoulos, N, Goula, A, Tolis, G.The role of luteinizing hormone activity in controlled ovarian stimulation. J Endocrinol Invest2005;28:79–88.Google Scholar
7
European Recombinant Human LH Study Group.Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab1998;83:1507–1514.Google Scholar
8
Lunenfeld, B.Historical perspectives in gonadotrophin therapy. Hum Reprod Update2004;10:453–467.Google Scholar
9
Rowe, PJ, Comhaire, FH, Hargreave, TB, et al. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge: Cambridge University Press; 1993.Google Scholar
10
Shoham, Z, Conway, GS, Patel, A, Jacobs, HS. Polycystic ovaries in patients with hypogonadotropic hypogonadism: similarity of ovarian response to gonadotropin stimulation in patients with polycystic ovarian syndrome. Fertil Steril1992;58:37–45.Google Scholar
11
Schachter, M, Balen, AH, Patel, A, Jacobs, HS. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone. Gynecol Endocrinol1996;10:327–335.Google Scholar
12
Muasher, SJ, Abdallah, RT, Hubayter, ZR. Optimal stimulation protocols for in vitro fertilization. Fertil Steril2006;86:267–273.Google Scholar
13
The Practice Committee of the American Society for Reproductive Medicine, Birmingham, Alabama. Gonadotropin preparations: past, present and future perspectives. Fertil Steril2008;90(5 Suppl):S13–S20.Google Scholar
14
Al-Inany, H, Aboulghar, MA, Mansour, RT, Proctor, M.Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum Reprod2006;21:569–570.Google Scholar
15
Bordewijk, EM, Mol, F, van der Veen, F, Van Wely, M.Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis. Hum Reprod Open2019;2019(3):hoz008.Google Scholar
16
van Wely, M, Kwan, I, Burt, AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev2011;2:CD005354.Google Scholar
17
The Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. Fertil Steril2008;90(5 Suppl):S7–S12.Google Scholar
18
Filicori, M, Cognigni, GE, Samara, A, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update2002;8:543–557.Google Scholar
19
Krause, BT, Ohlinger, R, Haase, A.Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review. Biologics2009;3:337–347.Google Scholar
20
Shoham, Z, Balen, A, Patel, A, Jacobs, HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertil Steril1991;56:1048–1053.Google Scholar
21
O’Dea, L, the US Recombinant Human LH Study Group. Recombinant LH in support of recombinant FSH in female hypogonadotropic hypogonadism-evidence of threshold effect. Fertil Steril2000;74(Suppl 1):S36.Google Scholar
22
Hagen, CP, Sørensen, K, Anderson, RA, Juul, A.Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril2012;98(5):1326–1330.Google Scholar
23
Sönmezer, M, Özmen, B, Atabekoglu, CS, et al. Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet2012;29(7):597–602.Google Scholar
24
Messinis, IE. Ovulation induction: a mini review. Hum Reprod2005;20:2688–2697.Google Scholar
25
Messinis, IE, Bergh, T, Wide, L.The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility. Fertil Steril1988;50(1):31–35.Google Scholar
26
Van der Linden, M, Buckingham, K, Farquhar, C, Kremer, JA, Metwally, M.Luteal phase support in assisted reproduction cycles. Hum Reprod Update2012;18(5):473.Google Scholar
27
Aboulghar, M.Luteal support in reproduction: when, what and how?Curr Opin Obstet Gynecol2009;21:279–284.Google Scholar
28
Kaufmann, R, Dunn, R, Vaughn, T, et al. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf)2007;67:563–569.Google Scholar
29
Shoham, Z, Smith, H, Yeko, T, et al. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf)2008;69:471–478.Google Scholar
30
Loumaye, E, Engrand, P, Shoham, Z, Hillier, SG, Baird, DT. Clinical evidence for an LH ‘ceiling’ effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod2003;18(2):314–322.Google Scholar
31
Awwad, JT, Farra, C, Mitri, F, et al. Split daily recombinant human LH dose in hypogonadotrophic hypogonadism: a nonrandomized controlled pilot study. Reprod Biomed Online2013;26(1):88–92.Google Scholar
32
le Cotonnec, JY, Loumaye, E, Porchet, H, Beltrami, V, Munafo, A.Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril1998;69(2):201–209.Google Scholar
33
Balasch, J, Fábregues, F, Carmona, F, Casamitjana, R, Tena-Sempere, M.Ovarian luteinizing hormone priming preceding follicle-stimulating hormone stimulation: clinical and endocrine effects in women with long-term hypogonadotropic hypogonadism. J Clin Endocrinol Metab2009;94:2367–2373.Google Scholar
34
Fluker, MR, Urman, B, Mackinnon, M, et al. Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet Gynecol1994;83:189–196.Google Scholar
35
Tadokoro, N, Vollenhoven, B, Clark, S, et al. Cumulative pregnancy rates in couples with anovulatory infertility compared with unexplained infertility in an ovulation induction programme. Hum Reprod1997;12:1939–1944.Google Scholar
36
Kumbak, B, Kahraman, S.Women with hypogonadotropic hypogonadism: cycle characteristics and results of assisted reproductive techniques. Acta Obstet Gynecol Scand2006;85:1453–1457.Google Scholar
37
Ghaffari, F, Arabipoor, A, Lankarani, NB, Etminan, Z, Tehraninejad, ES. Assisted reproductive technique outcomes in hypogonadotropic hypogonadism women. Ann Saudi Med2013;33(3):235–240.Google Scholar
38
Pandurangi, M, Tamizharasi, M, Reddy, NS. Pregnancy outcome of assisted reproductive technology cycle in patients with hypogonadotropic hypogonadism. J Hum Reprod Sci2015;8(3):146–150.Google Scholar
39
Yilmaz, S, Ozgu-Erdinc, AS, Yumusak, O, et al. The reproductive outcome of women with hypogonadotropic hypogonadism undergoing in vitro fertilization. Syst Biol Reprod Med2015;61(4):228–232.Google Scholar
40
Mumusoglu, S, Ata, B, Turan, V, et al. Does pituitary suppression affect live birth rate in women with congenital hypogonadotrophic hypogonadism undergoing intra-cytoplasmic sperm injection? A multicenter cohort study. Gynecol Endocrinol2017;33(9):728–732.Google Scholar
41
Cecchino, GN, Canillas, GM, Cruz, M, García-Velasco, JA. Impact of hypogonadotropic hypogonadism on ovarian reserve and response. J Assist Reprod Genet2019;36(11):2379–2384.Google Scholar
42
Kuroda, K, Ezoe, K, Kato, K, et al. Infertility treatment strategy involving combined freeze‐all embryos and single vitrified‐warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism. J Obstet Gynaecol Res2018;44(5):922–928.Google Scholar
43
Klemetti, R, Sevon, T, Gissler, M, Hemm, E.Complications of IVF and ovulation induction. Hum Reprod2005;20:3293–3300.Google Scholar
44
Aboulghar, M.Symposium: Update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online2009;19:33–42.Google Scholar
45
The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril2008;90(5 Suppl):S188–S193.Google Scholar
46
Mathur, R, Kailasam, C, Jenkins, J.Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. Hum Fertil2007;10:75–85.Google Scholar
47
Letterie, GS, Coddington, CC, Collins, RL, Merriam, GR. Ovulation induction using s.c. pulsatile gonadotrophin-releasing hormone: effectiveness of different pulse frequencies. Hum Reprod1996;11:19–22.Google Scholar
48
Homburg, R, Eshel, A, Armar, NA, et al. One hundred pregnancies after treatment with pulsatile luteinizing hormone releasing hormone to induce ovulation. Br Med J1989;298:809–812.Google Scholar
49
Braat, DD, Ayalon, D, Blunt, SM, et al. Pregnancy outcome in luteinizing hormone-releasing hormone induced cycles: a multicentre study. Gynecol Endocrinol1989;3:35–44.Google Scholar
50
Martin, KA, Hall, JE, Adams, JM, Crowley, WF Jr. Comparison of exogenous gonadotropins and pulsatile gonadotropin-releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab1993;77(1):125–129.Google Scholar
51
Mattle, V, Leyendecker, G, Wildt, L.Side effects of pulsatile GnRH therapy for induction of ovulation. Expert Rev Endocrinol Metab2008;3:535–538.Google Scholar
52
Filicori, M, Flamigni, C, Dellai, P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab1994;79(4):1215–1220.Google Scholar
53
Hall, R, Manski-Nankervis, J, Goni, N, Davies, MC, Conway, GS. Fertility outcomes in women with hypopituitarism. Clin Endocrinol2006;65:71–74.Google Scholar
Park, JK, Murphy, AA, Bordeaux, BL, Dominguez, CE, Session, DR. Ovulation induction in a poor responder with panhypopituitarism: a case report and review of the literature. Gynecol Endocrinol2007;23:82–86.Google Scholar
56
Homburg, R, West, C, Torresani, T, Jacobs, HS. Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial. Fertil Steril1990;53:254–260.Google Scholar
57
Giampietro, A, Milardi, D, Bianchi, A, et al. The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature. Fertil Steril2009;91(3):930.e7–930.e11.Google Scholar
58
Daniel, A, Ezzat, S, Greenblatt, E.Adjuvant growth hormone for ovulation induction with gonadotropins in the treatment of a woman with hypopituitarism. Case Rep Endocrinol2012;20:12.Google Scholar
59
Salle, A, Klein, M, Pascal-Vigneron, V, et al. Successful pregnancy and birth after sequential cotreatment with growth hormone and gonadotropins in a woman with panhypopituitarism: a new treatment protocol. Fertil Steril2000;74:1248–1250.Google Scholar
60
Harper, K, Proctor, M, Hughes, E.Growth hormone for in vitro fertilization. Cochrane Database Syst Rev2003;3:CD000099.Google Scholar
61
Jacobs, HS, Shoham, Z, Schachter, M, et al. Cotreatment with growth-hormone and gonadotropin for ovulation induction in hypogonadotropic patients-a prospective, randomized, placebo-controlled, dose-response study. Fertil Steril1995;64(5):917–923.Google Scholar
62
Curran, AJ, Peacey, SR, Shalet, SM. Is maternal growth hormone essential for a normal pregnancy?Eur J Endocrinol1998;139:54–58.Google Scholar
63
Menashe, Y, Sack, J, Mashiach, S.Spontaneous pregnancies in two women with Laron-type dwarfism: are growth hormone and circulating insulin-like growth factor mandatory for induction of ovulation?Hum Reprod1991;6:670–671.Google Scholar
64
Voutetakis, A, Sertedaki, A, Livadas, S, et al. Ovulation induction and successful pregnancy outcome in two patients with Prop1 gene mutations. Fertil Steril2004;82:454–457.Google Scholar
65
Yildirim, M, Noyan, V, Tiras, MB. Estrogen-progestagen pre-treatment before HMG induction in hypogonadotropic patients. Int J Gynaecol Obstet2000;71:249–250.Google Scholar
66
Hayashi, M, Tomobe, K, Hoshimoto, K, Ohkura, T.Successful pregnancy following gonadotropin therapy in a patient with hypogonadotropic hypogonadism resulting from craniopharyngioma. Int J Clin Pract2002;56:149–151.Google Scholar
67
Toumba, M, Sergis, A, Kanaris, C, Skordis, N.Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev2007;5:642–648.Google Scholar
68
Chatterjee, R, Bajoria, R.Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann N Y Acad Sci2010;1202(1):100–114.Google Scholar
69
Poggi, M, Sorrentino, F, Pugliese, P, et al. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Ann Hematol2016;95(5):757–763.Google Scholar
70
Pafumi, C, Farina, M, Pernicone, G, et al. At term pregnancies in transfusion-dependent beta-thalassemic women. Clin Exp Obstet Gynecol2000;27:185–187.Google Scholar
71
Skordis, N, Christou, S, Koliou, M, Pavlides, N, Angastiniotis, M.Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab1998;11(Suppl 3):935–943.Google Scholar
72
Karagiorga-Lagana, M.Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab1998;11(Suppl 3):945–951.Google Scholar
73
Cunningham, MJ, Macklin, EA, Muraca, G, Neufeld, EJ. Successful pregnancy in thalassemia major women in the Thalassemia Clinical Research Network. Pediatr Res2004;55:294A.Google Scholar
74
Tuck, SM. Fertility and pregnancy in thalassemia major. Ann N Y Acad Sci2005;1054:300–307.Google Scholar
75
Bajoria, R, Chatterjee, R.Current perspectives of fertility and pregnancy in thalassemia. Hemoglobin2009;33(Suppl 1):S131–S135.Google Scholar
76
Origa, R, Piga, A, Quarta, G, et al. Pregnancy and β-thalassemia: an Italian multicenter experience. Haematologica2010;95(3):376–381.Google Scholar
77
Dungan, HM, Clifton, DK, Steiner, RA. Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. Endocrinology2006;147:1154–1158.Google Scholar
78
Lee, JH, Miele, ME, Hicks, DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst1996;88:1731–1737.Google Scholar
79
Tena-Sempere, M.Kisspeptin signaling in the brain: recent developments and future challenges. Mol Cell Endocrinol2010;314:164–169.Google Scholar
80
Reynolds, RM, Logie, JJ, Roseweir, AK, McKnight, AJ, Millar, RP. A role for kisspeptins in pregnancy: facts and speculations. Reproduction2009;138:1–7.Google Scholar
81
Thompson, EL, Patterson, M, Murphy, KG, et al. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol2004;16:850–858.Google Scholar
82
Dhillo, WS, Chaudhri, OB, Thompson, EL, et al. Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab2007;92:3958–3966.Google Scholar
83
Roa, J, Aguilar, E, Dieguez, C, Pinilla, L, Tena-Sempere, M.New frontiers in kisspeptin/GPR54 physiology as fundamental gatekeepers of reproductive function. Front Neuroendocrinol2008;29:48–69.Google Scholar
84
Dekel, N.Master regulators of female infertility. N Engl J Med2009;361:718–719.Google Scholar
85
Fan, HY, Liu, Z, Shimada, M, et al. MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility. Science2009;324:938–941.Google Scholar
86
Xekouki, P, Tolis, G. Ovulation induction for hypogonadotropic hypogonadism. In: Aboulghar, M, Rizk, B, eds. Ovarian Stimulation. Cambridge: Cambridge University Press; 2011:162–172.Google Scholar